Atlas Trials

PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %

Clinical trial NCT04547504 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04547504
Sponsor
University Hospital, Brest
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Non-small-cell Lung Cancer
Start date
2020-12-22
Primary completion
2025-12-22
Enrollment
349

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.